Search results
Results from the WOW.Com Content Network
AbbVie will pay around $10 billion to add a potential blockbuster cancer treatment as cheaper versions of the drugmaker’s all-time best seller, Humira, cut into sales. ... the autoimmune disease ...
A recently published report by global pharma researcher Decision Resources suggests that forward growth in key European markets for AbbVie's flagship drug Humira, a treatment for autoimmune ...
AbbVie's success with Humira is a textbook example. Humira (adalimumab) is an immunosuppressant drug used to treat several autoimmune diseases, in which a patient's immune system attacks healthy ...
Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.
Daclizumab (trade name Zinbryta) is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). ). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-c
ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts. [2]
Inventiva (NASDAQ: IVA) said that AbbVie Inc (NYSE: ABBV) would stop developing cedirogant (ABBV-157), an oral RORg inverse agonist jointly discovered by Inventiva and AbbVie for autoimmune ...
Elotuzumab, sold under the brand name Empliciti, is a humanized IgG1 monoclonal antibody medication used in combination with lenalidomide and dexamethasone, for adults that have received 1 to 3 prior therapies for the treatment of multiple myeloma. [3]